A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Phase 3 Completed 84 enrolled UCB Biopharma SRL

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to investigate the long-term safety, tolerability and efficacy of brivaracetam in pediatric study participants with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).

Timeline

Start: 2022-03-30
Primary completion: 2025-03-18
Completion: 2025-03-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brivaracetam	Small molecule	10 mg	Oral
Subject	Brivaracetam	Small molecule	10 mg/ml	Oral
Subject	Brivaracetam	Small molecule	25 mg	Oral
Subject	Brivaracetam	Small molecule	50 mg	Oral

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Summary

Timeline

Drugs

Indications